期刊
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
卷 30, 期 1, 页码 19-22出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jvir.2018.06.023
关键词
-
资金
- Intramural Research Program of the National Institutes of Health
- Center of Interventional Oncology [ZID BC011242-10]
- Cooperative Research and Development agreement
- BTG/Biocompatibles
- NATIONAL CANCER INSTITUTE [ZICSC006537, ZIABC011343] Funding Source: NIH RePORTER
Differences in drug metabolism associated with UGT1A1 polymorphism could result in individualized local response to hepatic chemoembolization with irinotecan-eluting beads (DEBIRI) or predictable toxicities. Five patients with inoperable hepatic metastases from colorectal or anal malignancies treated with DEBIRI were assessed for UGT 1 AI mutations. No difference in area under the curve (AUC) for SN38 in normal liver and tumor tissue samples was noted with variant or wild-type UBT1A1 (P = .16 and P = .05, respectively). Plasma SN-38 AUC was significantly lower in wild-type compared to variant patients (P < .0001). UGT1A1 genotype may not be predictive of hematologic toxicity after DEBIRI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据